gabapentin has been researched along with Cerebral Infarction in 6 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Cerebral Infarction: The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).
Excerpt | Relevance | Reference |
---|---|---|
"To determine the relative tolerability and efficacy of two newer antiepileptic drugs, lamotrigine (LTG) and gabapentin (GBP), as compared to carbamazepine (CBZ) in older patients with epilepsy." | 9.11 | New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. ( Boardman, KD; Carter, GS; Collins, JF; Felicetta, J; Frederick, T; Marks, W; Pryor, F; Ramsay, RE; Rowan, AJ; Spitz, M; Tomyanovich, ML; Towne, A; Uthman, BM, 2005) |
"To determine the relative tolerability and efficacy of two newer antiepileptic drugs, lamotrigine (LTG) and gabapentin (GBP), as compared to carbamazepine (CBZ) in older patients with epilepsy." | 5.11 | New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. ( Boardman, KD; Carter, GS; Collins, JF; Felicetta, J; Frederick, T; Marks, W; Pryor, F; Ramsay, RE; Rowan, AJ; Spitz, M; Tomyanovich, ML; Towne, A; Uthman, BM, 2005) |
"Persistent hiccups have been reported to occur occasionally during rehabilitation hospitalizations." | 2.44 | Persistent hiccups during rehabilitation hospitalization: three case reports and review of the literature. ( Browne, BA; Schuchmann, JA, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kim, JB | 1 |
Yu, S | 1 |
Pistoia, F | 1 |
Sarà, M | 1 |
Kamiya, T | 1 |
Abe, K | 1 |
Rowan, AJ | 1 |
Ramsay, RE | 1 |
Collins, JF | 1 |
Pryor, F | 1 |
Boardman, KD | 1 |
Uthman, BM | 1 |
Spitz, M | 1 |
Frederick, T | 1 |
Towne, A | 1 |
Carter, GS | 1 |
Marks, W | 1 |
Felicetta, J | 1 |
Tomyanovich, ML | 1 |
Schuchmann, JA | 1 |
Browne, BA | 1 |
Moretti, R | 1 |
Torre, P | 1 |
Antonello, RM | 1 |
Nasuelli, D | 1 |
Cazzato, G | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epileps[NCT00438451] | Phase 4 | 361 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT00438451)
Timeframe: 58 weeks
Intervention | proportion of participants (Mean) |
---|---|
Levetiracetam | 0.61 |
Carbamazepine | 0.46 |
Lamotrigine | 0.56 |
Percentage of patients experiencing no seizures until week 58 (Visit 6) and did not discontinue the study until week 58. (NCT00438451)
Timeframe: week 58
Intervention | percentage of participants (Number) |
---|---|
Levetiracetam | 43 |
Carbamazepine | 33 |
Lamotrigine | 38 |
Percentage of patients experiencing no seizures until week 30 (Visit 4) and did not discontinue the study until week 30. (NCT00438451)
Timeframe: Week 30
Intervention | percentage of participants (Number) |
---|---|
Levetiracetam | 48 |
Carbamazepine | 39 |
Lamotrigine | 49 |
(NCT00438451)
Timeframe: 52 weeks
Intervention | proportion of seizure-free days (Number) |
---|---|
Levetiracetam | 0.99 |
Carbamazepine | 0.99 |
Lamotrigine | 0.99 |
EPITrack-Score shows the performance of attention and executive functions. Higher values indicate a better performance. The results of EPITrack Score ranges between 7 and 45. (NCT00438451)
Timeframe: week 58
Intervention | units on a scale (Mean) |
---|---|
Levetiracetam | 26.0 |
Carbamazepine | 26.0 |
Lamotrigine | 25.4 |
"Seizure frequency was assessed by investigators in the CRF at the Visits V3, V4, V5 and V6.~The absolute seizure frequency during the maintenance phase was defined as the sum of those entries." (NCT00438451)
Timeframe: over 52 weeks
Intervention | number of seizures (Number) |
---|---|
Levetiracetam | 168 |
Carbamazepine | 131 |
Lamotrigine | 130 |
(NCT00438451)
Timeframe: over the whole duration of 58 weeks
Intervention | days (Median) |
---|---|
Levetiracetam | NA |
Carbamazepine | NA |
Lamotrigine | NA |
number of days between randomization and premature discontinuation of the study (NCT00438451)
Timeframe: 58 weeks
Intervention | days (Median) |
---|---|
Levetiracetam | NA |
Carbamazepine | 265 |
Lamotrigine | NA |
"The PNS is a 15-item scale. Each item can be scored from 1 to 9. There are a total score (includes all items, range:15 to 135) and two subscores: The cognitive toxicity subscore (10 items: Energy Level, Memory, Interest, Concentration, Forgetfulness, Sleepliness, Moodiness, Alertness, Attention Span, Motivation, range:10 to 90) and the somatomoto subscore (5 items: Vision, Walking, Coordination, Tremor, Speech, range:5-45). The score is calculated by taking the mean of all non-missing values times the number of items.~Lower values indicate better quality of life." (NCT00438451)
Timeframe: at week 58
Intervention | units on a scale (Mean) | ||
---|---|---|---|
Cognitive toxicity subscore | Somatomotor subscore | Total Score | |
Carbamazepine | 27.3 | 11.4 | 38.7 |
Lamotrigine | 23.7 | 10.8 | 34.5 |
Levetiracetam | 22.2 | 10.5 | 32.7 |
The QOLIE-31 is a 31 item score that measures the quality of life in epilepsy (each item with a range of 0 to 100). There are 7 sub-scores seizure worry (items 11,21,22,23,25), overall quality of life (items 1,14), emotional well-being (items 3,4,5,7,9), energy/fatigue (items 2,6,8,10), cognitive functioning (items 12,15,16,17,18,26), medication effects (items 24,29,30) and social functioning (13,19,20,27,28). These scores were combined to a total score by Total score = seizure worry*0.08 + overall quality of life*0.14 + emotional well-being*0.15 + energy/fatigue*0.12 + cognitive functioning*0.27 + medication effects*0.03 + social functioning*0.21 For all scores, higher values indicate better quality of life. Each score has a possible range from 0 to 100. (NCT00438451)
Timeframe: 58 weeks, final visit
Intervention | units on a scale (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Seizure worry | Overall quality of life | Emotional well-being | Energy/fatigue | Cognitive functioning | Medication effects | Social functioning | Total Score | Health Scale | |
Carbamazepine | 75.4 | 65.0 | 69.8 | 54.5 | 68.9 | 70.6 | 76.3 | 68.9 | 65.7 |
Lamotrigine | 75.0 | 67.1 | 67.4 | 59.8 | 68.0 | 72.6 | 76.7 | 69.1 | 67.5 |
Levetiracetam | 85.1 | 67.2 | 72.0 | 60.8 | 75.1 | 77.6 | 81.1 | 73.9 | 69.5 |
"Evaluation of current testing at V6:~≥29 score points: Inconspicuous; 26 to 28 score points: Borderline;~≤25 score points: Impaired" (NCT00438451)
Timeframe: 58 weeks
Intervention | participants (Number) | ||
---|---|---|---|
Without pathological findings | Borderline | Impaired | |
Carbamazepine | 34 | 17 | 33 |
Lamotrigine | 31 | 15 | 39 |
Levetiracetam | 38 | 10 | 36 |
"Evaluation of Changes~Changes in the EpiTrack® Score were categorized as follows:~≥5 score points: Improved;~-3 to 4 score points: Unchanged;~≤-4 score points: Worsened" (NCT00438451)
Timeframe: week 58
Intervention | participants (Number) | ||
---|---|---|---|
Improved | Unchanged | Worsened | |
Carbamazepine | 16 | 56 | 8 |
Lamotrigine | 15 | 53 | 13 |
Levetiracetam | 15 | 61 | 6 |
2 reviews available for gabapentin and Cerebral Infarction
Article | Year |
---|---|
[Future neuroprotective strategies in the post-thrombolysis era--neurovascular unit protection and vascular endothelial protection].
Topics: Amines; Animals; Antipyrine; Cerebral Infarction; Cyclohexanecarboxylic Acids; Edaravone; Endotheliu | 2011 |
Persistent hiccups during rehabilitation hospitalization: three case reports and review of the literature.
Topics: Aged; Amines; Anti-Anxiety Agents; Anticonvulsants; Cerebral Infarction; Chlorpromazine; Chronic Dis | 2007 |
2 trials available for gabapentin and Cerebral Infarction
Article | Year |
---|---|
New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine.
Topics: Aged; Aging; Amines; Anticonvulsants; Carbamazepine; Cerebral Infarction; Cyclohexanecarboxylic Acid | 2005 |
Treatment of chronic: new perspectives.
Topics: Acetates; Aged; Amines; Cerebral Infarction; Chronic Disease; Cyclohexanecarboxylic Acids; Excitator | 1999 |
2 other studies available for gabapentin and Cerebral Infarction
Article | Year |
---|---|
Neurological picture. Trigeminal neuralgia after pontine infarction affecting the ipsilateral trigeminal nerve.
Topics: Amines; Analgesics, Non-Narcotic; Carbamazepine; Cerebral Infarction; Cyclohexanecarboxylic Acids; G | 2013 |
Gabapentin therapy for ocular opsoclonus-myoclonus restores eye movement communication in a patient with a locked-in syndrome.
Topics: Adult; Amines; Anticonvulsants; Cerebral Infarction; Cyclohexanecarboxylic Acids; Female; Gabapentin | 2010 |